REGENXBIO Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $170.4M | $83.3M | $90.2M | $112.7M | $470.3M | $154.6M | $35.2M | $218.5M |
| Cost of Revenue | — | $33.6M | $37.2M | $54.5M | $51.8M | $35.7M | $8.2M | $9.6M |
| Gross Profit | — | $49.8M | $53.0M | $58.2M | $418.5M | $118.9M | $27.0M | $208.9M |
| Gross Margin | — | 59.7% | 58.8% | 51.6% | 89.0% | 76.9% | 76.6% | 95.6% |
| Operating Expenses | ||||||||
| Research & Development | $228.3M | $208.5M | $232.3M | $242.5M | $181.4M | $166.3M | $124.2M | $83.9M |
| SG&A Expense | $82.9M | $76.6M | $88.5M | $85.3M | $79.3M | $63.8M | $51.8M | $36.9M |
| Operating Income | $-161.2M | $-233.3M | $-268.1M | $-262.9M | $160.0M | $-119.2M | $-149.0M | $88.1M |
| Operating Margin | -94.6% | -280.0% | -297.1% | -233.2% | 34.0% | -77.1% | -422.9% | 40.3% |
| Interest Expense | — | — | $6.9M | $23.3M | $26.3M | $771.0K | — | — |
| Pretax Income | $-193.9M | $-227.1M | $-263.6M | $-280.4M | $141.2M | $-106.0M | $-97.5M | $104.1M |
| Income Tax Expense | $0 | $0 | $-152.0K | $-84.0K | $13.4M | $5.2M | $-2.8M | $4.2M |
| Net Income | $-193.9M | $-227.1M | $-263.5M | $-280.3M | $127.8M | $-111.3M | $-94.7M | $99.9M |
| Net Margin | -113.8% | -272.5% | -292.0% | -248.7% | 27.2% | -72.0% | -268.9% | 45.7% |
| EPS (Basic) | $-3.76 | $-4.59 | $-6.02 | $-6.50 | $3.01 | $-2.98 | $-2.58 | $2.99 |
| EPS (Diluted) | $-3.76 | $-4.59 | $-6.02 | $-6.50 | $2.91 | $-2.98 | $-2.58 | $2.73 |
| Shares Outstanding (Basic) | 51.6M | 49.5M | 43.7M | 43.2M | 42.4M | 37.3M | 36.7M | 33.4M |
| Shares Outstanding (Diluted) | 51.6M | 49.5M | 43.7M | 43.2M | 43.9M | 37.3M | 36.7M | 36.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |